Knight Therapeutics Inc. (OTCMKTS:KHTRF – Get Free Report)’s stock price traded down 0.9% during mid-day trading on Thursday . The company traded as low as $6.89 and last traded at $6.8940. Approximately 6,276 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 8,267 shares. The stock had previously closed at $6.96.
Analyst Upgrades and Downgrades
Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy”.
View Our Latest Analysis on Knight Therapeutics
Knight Therapeutics Stock Performance
About Knight Therapeutics
Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.
Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.
Further Reading
- Five stocks we like better than Knight Therapeutics
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
